Life Sciences

  • May 12, 2026

    Makary Out As FDA Commissioner, Trump Says

    U.S. Food and Drug Administration Commissioner Marty Makary is departing the agency, President Donald Trump confirmed on Tuesday, bringing to an end a tumultuous, one-year run as one of the nation's top health officials.

  • May 12, 2026

    SPAC, Investors Sue Aesthetics Co. Over Failed $250M Merger

    Viveon Health Acquisition Corp., a SPAC, and several investors have sued Townsgate Village Inc., formerly known as Suneva Medical Inc., in the Delaware Chancery Court, alleging that the aesthetics company strung them along in a failed $250 million special purpose acquisition company merger while secretly looking for another deal.

  • May 12, 2026

    FDA Leaders Outline How AI Is Shaping The Agency's Work

    The U.S. Food and Drug Administration is using generative artificial intelligence to help redact records before public release, summarize documents and evaluate scientific literature, federal officials said in a recent conference.

  • May 12, 2026

    Celgene Gets Final OK For $239M Deal, Atty Fees

    Investors in biopharmaceutical company Celgene Corp. have gotten a final nod for their $239 million deal to end proposed class claims that the company overstated commercial prospects for two of its drugs, and the investors' four-firm legal team will get fees and costs of nearly $57.3 million for their work on the case.

  • May 12, 2026

    Female Medtronic Manager's Firing Driven By Bias, Court Told

    Medtronic fired a longtime manager for disciplining a male subordinate and raising concerns about gender discrimination and retaliation, the worker told a Colorado state court.

  • May 11, 2026

    NJ Justices Back Coverage Exclusion Reservation Of Rights

    The New Jersey Supreme Court on Monday said an insurer doesn't waive its right to rely on a policy exclusion after initially defending a claim, backing Berkley Insurance Co. in a coverage dispute stemming from self-dealing suits against a pharmaceutical company and its chairman.

  • May 11, 2026

    Wash. Says Novartis Isn't Harmed By 340B Drug Pricing Law

    Washington is objecting to Novartis' attempt to block a state law that expands the discounts the drugmaker must provide under the federal 340B Drug Pricing Program, telling a federal court that worry about losing money doesn't constitute irreparable harm.

  • May 11, 2026

    Nestlé Sues To Unmask Amazon Sellers Of 'Stolen' Vitamins

    Nestlé Health Science U.S. filed a lawsuit in Washington state Friday in an effort to unmask "suspected bad actors" whom it accuses of illegally intercepting high volumes of nutritional supplements and funneling them to resellers on Amazon.com.

  • May 11, 2026

    Mead Johnson Heads To Trial In Ill. Baby Formula MDL

    An Illinois federal judge handling multidistrict litigation over baby formula that allegedly caused a serious abdominal condition in premature infants rejected Mead Johnson & Co. LLC's summary judgment bid in the fourth lawsuit parties had selected as an MDL tester case, teeing up the litigation's first trial.

  • May 11, 2026

    Beauty Tech Co. Execs Beat Investor Suit For Good

    A California federal judge Monday tossed a proposed class action accusing beauty technology firm Cutera and its executives of misleading investors about its acne treatment launch and financial results, finding the legal claims against the company were abandoned and discharged under its Chapter 11 plan.

  • May 11, 2026

    Pharma CEO's Role In Ex-Exec's Contract Permits Deposition

    North Carolina's business court has refused to shield the CEO of biopharmaceutical firm United Therapeutics Corp. from being deposed in a trade secrets lawsuit against a former executive and his new employer, finding it reasonable to believe she was an "ultimate decision-maker."

  • May 11, 2026

    Amgen Late To Raise Double-Taxation Claim, Tax Court Told

    Biotechnology giant Amgen is making a "futile" attempt to raise a purported double-taxation issue for tax years 2016 through 2018 in a pair of transfer pricing cases before the U.S. Tax Court, the federal government said, arguing the disputed years fall outside the court's jurisdiction.

  • May 11, 2026

    Trading Scheme Is A 'Wake-Up Call' For BigLaw Compliance

    The breadth of a decade-long insider trading scheme prosecutors say was fueled by stolen BigLaw merger information should jolt firms to reexamine their practices to close gaps in internal security, experts told Law360, even if totally eliminating bad actors is nearly impossible.

  • May 11, 2026

    Justices Extend Stay On 5th Circ. Mifepristone Decision

    The U.S. Supreme Court on Monday extended a stay that preserved, for now, telehealth access to the abortion medication mifepristone.

  • May 11, 2026

    Fed. Circ. Backs Atty Fee Ruling In Bone Fusion Patent Row

    The Federal Circuit on Monday backed a lower court that awarded $52,573 in attorney fees for Nextremity Solutions Inc.'s defense against a bone fusion patent suit and shot down Nextremity's bid for $343,660 in fees incurred at the Patent Trial and Appeal Board.

  • May 11, 2026

    Plaintiffs' Attys Sanctioned In Tylenol MDL, Sparking Appeal

    A New York federal court sanctioned a plaintiffs' firm and its co-founder in federal multidistrict litigation by families alleging that prenatal exposure to acetaminophen can cause autism, saying they improperly shared confidential information from the case in related state court actions.

  • May 08, 2026

    Ex-FDA Chief Says J&J Atty 'Spinning' Asbestos Definition

    A former U.S. Food and Drug Administration commissioner told an attorney for Johnson & Johnson she was "spinning" the definition of asbestos in an attempt to confuse a jury in a bellwether trial over claims the company's talc products caused three women's deaths from ovarian cancer.

  • May 08, 2026

    FTC's Gender-Care Probe Likely Retaliatory, Judge Says

    The Endocrine Society has convinced a D.C. federal judge that the Federal Trade Commission's motivation for targeting it with a subpoena was likely retaliation for the guidelines the nonprofit produced regarding gender-affirming care.

  • May 08, 2026

    10x, Curio Settle Genomics Patent Suit Before Trial

    10x Genomics on Friday said it has agreed to end its suit accusing Curio Bioscience of infringing a series of Prognosys Biosciences genomics technology patents that 10x Genomics is licensed to use.

  • May 08, 2026

    Sports Tech Co. Says Judge Made Own Patent Eligibility Case

    Finnish sports tech company Polar Electro has asked the U.S. Supreme Court to revive its infringement case against a rival over a heart monitoring patent, saying a district judge made up his own case for patent eligibility when he ruled the patent was invalid.

  • May 08, 2026

    10x, Harvard Sue Sequencing Co. Over Biology Patents

    10x Genomics Inc. and Harvard have sued Element Biosciences Inc. in Delaware federal court, accusing the San Diego sequencing company of infringing four Harvard-owned patents through Element's AVITI24 platform and related Teton chemistry.

  • May 08, 2026

    Ex-Wachtell Lipton Atty Tied To Stolen BigLaw Info Trades

    A former Wachtell Lipton Rosen & Katz attorney who later worked for investment bank LionTree LLC is an unindicted co-conspirator in a sweeping alleged insider trading scheme that involved stolen information from several prominent law firms, according to a review of publicly available information.

  • May 08, 2026

    Covington, Cooley Lead Drugmaker Odyssey's $279M IPO

    Venture-backed biotechnology firm Odyssey Therapeutics began trading publicly Friday after raising $279 million in its initial public offering, making it the latest biotech to hit the public markets over the last few weeks.

  • May 08, 2026

    Squires Says Yes To 7 Patent Petitions, No To A Dozen More

    U.S. Patent and Trademark Office Director John Squires granted seven petitions for patent review under the America Invents Act and denied 12 other petitions, including a host of challenges by Cisco Systems and Samsung Electronics.

  • May 08, 2026

    Don't Miss It: Paul Hastings, V&E Steer Latest Hot Deals

    A lot can happen in the world of mergers and acquisitions and equity fundraising over the course of a couple weeks, and it's difficult to keep up with all the deals.

Expert Analysis

  • Series

    Law School's Missed Lessons: The Human Element

    Author Photo

    Law school teaches you to quickly apply intellect and logic when handling a legal issue, but every fact pattern also involves a person, making the ability to balance expertise with empathy critical to the growth of relationships with clients, colleagues and adversaries, says Rachel Adcox at Adcox Strategies.

  • Avoid The Unexpected When Drafting License Agreements

    Author Photo

    The Delaware Court of Chancery's recent decision in Commave v. Zevrain raises several practice points for attorneys drafting commercial contracts, underscoring the importance of considering anti-assignment provisions, specific exclusions and potential carveouts when drafting license agreements or other commercial contracts, say attorneys at Hogan Lovells.

  • CMS Healthcare Enforcement Initiatives May Cause Disruption

    Author Photo

    The Centers for Medicare & Medicaid Services' recently announced enforcement actions against healthcare fraud mark a significant escalation, and CMS' prior approach in the hospice sector suggests that even compliant providers and suppliers should brace for impact, say attorneys at Morgan Lewis.

  • The Benefits Of Choosing A Niche Practice In The AI Age

    Author Photo

    As artificial intelligence becomes increasingly accessible, lawyers with a niche practice may stand out as clients seek specialized judgment that automation cannot replicate, but it is important to choose a niche that is durable, engaging and a good personal fit, says Daniel Borneman at Lowenstein Sandler.

  • How PBMs Can Adapt To Plan Sponsors' Disclosure Demands

    Author Photo

    As federal reforms, growing state regulation and litigation threats push plan sponsors to expect visibility into revenue streams, pharmacy benefit managers should leverage transparency strategically, including by simplifying how they get paid, offering clients audit-ready data and co-designing contracts that are easy for fiduciaries to explain and defend, says Kristie Blase at Frazer + Blase.

  • What New Animal Welfare Enforcement Push Means For Cos.

    Author Photo

    The Trump administration's recently announced multiagency focus on violations of the Animal Welfare Act and related laws will likely lead to broader enforcement actions across industries, heightened scrutiny of compliance standards and a need for businesses to adopt effective risk management practices, says Shennie Patel at Crowell & Moring.

  • How To Engage With Gov't's Direct-To-Consumer Drug Policy

    Author Photo

    The U.S. Department of Health and Human Services' recent request for industry input on manufacturers' direct-to-consumer drug sales reflects the government's caution in this arena, and allows stakeholders a rare opportunity to help shape policy, says Mary Kohler at Kohler Health Law.

  • Series

    Podcasting Makes Me A Better Lawyer

    Author Photo

    Podcasting has changed how I ask questions and connect with people, sharpening my ability to listen without interrupting or prejudging, and bringing me closer to what law is meant to be: a human profession grounded in understanding, judgment and trust, says Donna DiMaggio Berger at Becker.

  • Patent Eligibility Bulletin: Steps To Consider As USPTO Shifts

    Author Photo

    Recent memoranda from the U.S. Patent and Trademark Office, along with some of the first patents issued under Director John Squires, indicate a recalibration of the subject matter eligibility landscape, signaling a renewed emphasis on concrete technological improvements and a potentially pro-AI stance, say attorneys at Banner Witcoff.

  • Tax Court Ruling Signals Cross-Border Loan Scrutiny

    Author Photo

    The U.S. Tax Court’s recent decision in Aventis v. Commissioner compounds ongoing regulatory focus on debt originations and should prompt practitioners to assess their existing cross-border lending structures for potential exposure to U.S. federal income tax, say attorneys at Eversheds.

  • Lessons From Justices' Split On Major Questions Doctrine

    Author Photo

    The justices' varied opinions in Learning Resources v. Trump, which held the International Emergency Economy Powers Act did not confer the power to impose tariffs, offer a meaningful window into the U.S. Supreme Court's perspective on the major questions doctrine that will likely shape lower courts' approach to executive action challenges, say attorneys at Venable.

  • Drug Wholesaler's DPA Shows Imperfect Efforts Still Count

    Author Photo

    Atlantic Biologicals’ recent deferred prosecution agreement with federal prosecutors for allegedly distributing controlled substances to pill mill pharmacies demonstrates that even subpar cooperation, when combined with genuine remediation and strategic advocacy, can yield outcomes that protect a company's long-term interests, says Jonathan Porter at Husch Blackwell.

  • Key Takeaways As HRSA Aims To Revive 340B Rebate Pilot

    Author Photo

    The U.S. Department of Health and Human Services' recent request for feedback on the 340B Rebate Model Pilot Program demonstrates that it intends to correct the model's procedural defects, which is positive news for participating manufacturers, but a setback for covered entities, say attorneys at Manatt.

  • When MDLs Drag, State Courts Can Speed Mass Tort Results

    Author Photo

    Understanding the structural dynamics that can delay resolution in multidistrict litigation is essential to understanding why a state court strategy is sometimes not merely attractive, but necessary for plaintiffs seeking timely and just outcomes, say attorneys at DiCello Levitt.

  • Leveraging MDLs And State Courts In Mass Tort Strategy

    Author Photo

    Multidistrict litigation's quiet drift from a pretrial coordination device to a de facto national court for mass torts poses a strategic question for plaintiffs counsel — whether an MDL will yield timely trials, meaningful accountability and fair value for clients, or whether a state court strategy will be more effective, say attorneys at DiCello Levitt.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.